Echinocandins: What role in the future?

Infectious Diseases in Clinical Practice

Volumn 13, Issue 4, 2005, Pages 149-151

  Kauffman, Carol A ^a,b  

^a UNIVERSITY OF MICHIGAN MEDICAL SCHOOL   (United States)

^b VA ANN ARBOR HEALTHCARE SYSTEM   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

AMPHOTERICIN B; ANIDULAFUNGIN; CARBAMAZEPINE; CASPOFUNGIN; CYCLOSPORIN; CYTOCHROME P450; ECHINOCANDIN; FLUCONAZOLE; MICAFUNGIN; PHENYTOIN; RIFAMPICIN; TRIAZOLE DERIVATIVE; VORICONAZOLE;

ANTIFUNGAL ACTIVITY; ASPERGILLOSIS; ASPERGILLUS; CANDIDA; CANDIDIASIS; CHILL; CLINICAL TRIAL; CRYPTOCOCCUS NEOFORMANS; DRUG ABSORPTION; DRUG APPROVAL; DRUG BLOOD LEVEL; DRUG EFFICACY; DRUG HYDROLYSIS; DRUG INDICATION; DRUG INFUSION; DRUG MECHANISM; DRUG SAFETY; EDITORIAL; FLUSHING; FOOD AND DRUG ADMINISTRATION; FUNGAL CELL; FUNGICIDAL ACTIVITY; HUMAN; LIVER TOXICITY; MINIMUM INHIBITORY CONCENTRATION; MYCOSIS; NONHUMAN; PHLEBITIS; SIDE EFFECT; SKIN MANIFESTATION; TOXICITY TESTING; ZYGOMYCETES;

EID: 22644441330     PISSN: 10569103     EISSN: None     Source Type: Journal    
DOI: 10.1097/01.idc.0000173273.57326.d8     Document Type: Editorial

References (16)

1. Ghannoum M, D'Angelo M. Anidulafungin: a potent antifungal that targets Candida and Aspergillus. Infect Dis Clin Pract. This issue.
2. Denning DW. Echinocandin antifungal drugs. Lancet. 2003;362: 1142-1151.
3. Deresinski SC, Stevens DA. Caspofungin. Clin Infect Dis. 2003;36: 1445-1457.
4. Maertens J, Raad I, Petrikkos G, et al. Efficacy and safety of caspofungin for treatment of invasive aspergillosis in patients refractory to or intolerant of conventional antifungal therapy. Clin Infect Dis. 2004;39:1563-1571.
5. Villanueva A, Gotuzzo E, Arathoon E, et al. A randomized double-blind study of caspofungin versus fluconazole for the treatment of esophageal candidiasis. Am J Med. 2002;113:294-299.
6. de Wet N, Llanos-Cuentas A, Suleiman J, et al. A randomized, double-blind, parallel-group, dose-response study of micafungin compared with fluconazole for the treatment of esophageal candidiasis in HIV-positive patients. Clin Infect Dis. 2004;39:842-849.
7. Krause DS, Sinjee AE, van Rensburg C, et al. A randomized, double-blind trial of anidulafungin versus fluconazole for the treatment of esophageal candidiasis. Clin Infect Dis. 2004;39:770-775.
8. Mora-Duarte J, Betts R, Rotstein C, et al. Caspofungin vs amphotericin B deoxycholate in the treatment of invasive candidiasis in neutropenic and non-neutropenic patients: a multi-centre, randomized, double-blind study. N Engl J Med. 2002;347:2020-2029.
9. Nevado J, De Alarcon A, Hernandez A. Caspofungin: a new therapeutic option for fungal endocarditis. Clin Microbiol Infect. 2005;11:248.
10. Krause DS, Reinhardt J, Vazquez JA, et al. Phase 2, randomized, dose-ranging study evaluating the safety and efficacy of anidulafungin in invasive candidiasis and candidemia. Antimicrob Agents Chemother. 2004;48:2021-2024.
11. Ostrosky-Zeichner L, Anaissie E, Kontoyiannis D, et al. Micafungin, an echinocandin antifungal agent for the treatment of new and refractory candidemia. Focus on Fungal Infections. 13 March 2003. Abstract 35.
12. Van Burik JH, Ratanatharathorn V, Stepan DE, et al. Micafungin versus fluconazole for prophylaxis against invasive fungal infections during neutropenia in patients undergoing hematopoietic stem cell transplantation. Clin Infect Dis. 2004;39:1407-1416.
13. Aliff TB, Maslak PG, Jurcic JG, et al. Refractory Aspergillus pneumonia in patients with acute leukemia: successful therapy with combination caspofungin and liposomal amphotericin B. Cancer. 2003;97:1025-1032.
14. Kontoyiannis DP, Hachem R, Lewis RE, et al. Efficacy and toxicity of caspofungin in combination with amphotericin B as primary or salvage treatment of invasive aspergillosis in patients with hematologic malignancies. Cancer. 2003;98:292-299.
15. Marr KA, Boeckh M, Carter RA, et al. Combination antifungal therapy for invasive aspergillosis. Clin Infect Dis. 2004;39:797-802.
16. Ratanatharathorn V, Flynn P, van Burik J, et al. Micafungin in combination with systemic antifungal agents in the treatment of refractory aspergillosis in bone marrow transplant patients. Am Soc Hematol. December 2002. Abstract 2472.